Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.255 -2.695 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.29 Bil PE Ratio: 0 PB Ratio: 1,065.02 GF Score: 78/100

Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call Transcript

Feb 15, 2024 / 01:30PM GMT
Release Date Price: $147.43 (-10.19%)
Operator

Good day, and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q4 2023 Earnings Conference Call. (Operator Instructions). After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference call over to the company.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam.

With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. Also on the line and available for Q&A is Akshay Vaishnaw, Chief Innovation Officer.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.

During

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot